DEVELOPMENT AND IN VIVO EVALUATION OF TOLCAPONE CONTROLLED RELEASE TRILAYER MATRIX TABLETS BY GEOMATRIX TECHNOLOGY
Objective: The present study was aimed to develop once-daily controlled release tri-layer matrix tablets of tolcapone, to achieve zero-order drug release for sustained plasma concentration by Geomatrix.
Methods: Tolcapone trilayer matrix tablets were prepared by direct compression method and consisted of active middle layer with different grades of hydroxypropyl methylcellulose (HPMC), ethyl cellulose and sodium CMC. Barrier layers were prepared with Eudragit L100-55, guar gum, sodium CMC and DCP.
Results: Based on the evaluation parameters, drug dissolution profile and release order kinetics, formulation HF16 was found to be optimized formulation. The developed drug delivery system provided prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation (HF16) was described by the zero-order and best fitted to Higuchi model. FT-IR and DSC studies confirmed that there was no chemical interaction between drug and excipients used in the formulation. The Tmax of the optimized formulation HF16 was significantly different (p<0.05) from that of the marketed product. Low Tmax value for the marketed product (2.02Â±0.02 h) indicates rapid absorption while the higher Tmax of the optimized formulation (6.00Â±0.04 h) suggests slower absorption. This delayed absorption of test preparation is most likely due to the sustained release of the drug.
Conclusion: The results indicate that the approach used could lead to a successful development of a controlled release formulation of the drug. In vivo studies revealed that the optimized formulation HF16 was shown significant plasma concentration with the controlled release and maintained for 24 h with patient compliance by reducing the dosage frequency when compared with Marketed product in the efficient management of Parkinsonâ€™s disease.
Keywords: Tolcapone, Eudragit L100-55, Geomatrix, Tri-layer matrix tablet, In vivo bioavailability studies
2. Conte U, Maggi L, Colombo P, La Manna A. Multi-layered hydrophilic matrices as constant release devices. J Controlled Release 1993;26:39-47.
3. Yihong Qui, Chidambaram N, Kolette F. Design and evaluation of layered diffusional matrices for zero order sustained-release tablets. J Controlled Release 1998;51:123-30.
4. Gohel MC, Parikh RK, Padshala MN, Sarvaiya KG, Jena DG. Formulation and optimization of directly compressible isoniazid are modified release matrix tablet. Indian J Pharm Sci 2007;69:640-5.
5. Tobyn MJ, Stani forth JN, Baichwal AR, Mc Call TW. Prediction of physical properties of a novel polysaccharide controlled release system. Int J Pharm 1996;128:113-22.
6. Talukdar MM, Mooter VD, Augustijns P, Maga TT, Verbeke N, Kinget R. In vitro evaluation of xanthan gum as potential excipients for oral controlled release matrix tablet formulation. Int J Pharm 1998;169:105-13.
7. Talukdar MM, Vercammen JP. Evaluation of xanthan gum as a hydrophillic matrix for controlled release dosage forms. Drug Dev Ind Pharm 1993;19:1037-46.
8. Hong Wen, Kinam Park. Oral controlled formulation release design and drug delivery, Theory to practice, Wiley publication, New Jercy; 2010. p. 94-5.
9. Napolitano A, Del Dotto P, Petrozzi L. Pharmacokinetics and pharmacodynamics of l-dopa after acute and 6-week tolcapone administration in patients with Parkinsonâ€™s disease. Clin Neuropharmacol 1999;22:24â€“9.
10. Keating GM, Lyseng-Williamson KA. Tolcapone. A review of its use in the management of Parkinsonâ€™s disease. CNS Drugs 2005;29:165â€“84.
11. Subrahmanyam C.V.S. Textbook of Physical Pharmaceutics. 11th edition. NK Jain. Publisher for Vallabh Prakashan; 2013. p. 215-24.
12. Sinko PJ. Martinâ€™s physical pharmacy and pharmaceutical sciences. Published by Wolters Klwner Health Pvt. Ltd, New Delhi; 2007. p. 553-9.
13. Efentakis M, Peponaki C. Formulation study and evaluation of matrix and three-layer tablet sustained drug delivery systems based on carbopols with isosorbite mononitrate. AAPS PharmSciTech 2008;9:917â€“23.
14. Jaison D, Elango K, Sundar Raj V, Dhunmati K, Kousalya M. Design development and evaluation of trilayer swelling gastro retentive tablets of lornoxicam for biphasic release and lansoprazole for immediate release for the treatment of arthritis. Int J Pharm Res Rev 2015;4:11-21.
15. Romulo Pereira Ribeiro, Cleverson Gasparetto J, Raquel de Oliveira V. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLCâ€“MS/M Smethod. Bioanalysis 2015;7:207-20.